New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: Adagene, Antengene, Ascentage, Beigene, Bluebird, Celcuity, Celldex, Eli Lilly, Geneleap, Greenwich, Heat, Immunocore, Immunogen, Innovent, Psioxus, Replimune, Sotio, Sound, Spectrum, SQZ, Sumitomo, Synthekine, Tachyon, Taiho, Tallac, TCR2, Theratechnologies, Treovir, Trisalus, Ultimovacs, Vincerx, Xencor, Y-mabs, Zentalis, Zymeworks.

Speaking during the 2021 China Pharmaceutical Innovation 100 Summit, industry insiders called for more regulatory talent and even an organizational revamp to clear innovative products faster and support the global development strategies of Chinese drugmakers.

SHANGHAI – China’s regulatory environment has evolved to encourage drug innovation, but despite remarkable progress, mounting pricing pressure from the government and a weak insurance sector remain as barriers.

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: BMS, Kronos, Kymera, Medicenna, Medigene, Mei, Mersana, Mirati, Molecular Partners, Molecular Templates, Morphic, Nextcure, Nuvalent, Oasmia, Oncolytics, Oncomyx, Oncurious, Oncternal, Oric, Pharmabcine, Phio, Pieris, PMV, Puretech, Schrodinger, Seneca.

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: Achilles, Advaxis, Affimed, Agenus, Alpine, Amphivena, Amunix, Arch, Arcus, Bayer, Beigene, Bio-Path, Black Diamond, Briacell, C4, Cardiff Oncology, Checkmate, Clovis, Codiak, Crispr, Elevation, Eli Lilly, Essa, F-star, Fusion, Gennao, Genprex, Glycomimetics, Gracell, GT, Hookipa, Hummingbird, Mirati, Instil, Intra-Cellular, Immune-Onc, Immunogen, Iteos, Jubilant, Kezar, Kineta, Kintara.

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: Affimed, Atyr, Chemocentryx, Greenwich, Humanigen, Imcheck, In8bio, Iovance, Mina, Nimbus, Onxeo, Sana, Sanofi, Surface Oncology, Transgene, Turning Point.

After climbing nearly 37% since the start of the week, shares of Greenwich Lifesciences Inc. (NASDAQ:GLSI) gained another 6% on April 9 as it disclosed new data bolstering the case for its cancer immunotherapy candidate, GP2. The data, to be presented at the American Association for Cancer Research annual meeting on Saturday, showed that when HER2-positive breast cancer patients had GP2 added to standard-of-care Herceptin (trastuzumab, Roche Holding AG) following breast cancer surgery, no recurrences of their cancer were observed, even after a median follow-up of five years.